Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  12/31/1969
Imperial Health, LLP
1483
mi
from 02139
Lake Charles, LA
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 12/31/1969
Imperial Health, LLP
1483
mi
from 02139
Lake Charles, LA
Click here to add this to my saved trials
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  12/31/1969
CentraCare Heart & Vascular Center @ St. Cloud Hospital
1163
mi
from 02139
Saint Cloud, MN
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 12/31/1969
CentraCare Heart & Vascular Center @ St. Cloud Hospital
1163
mi
from 02139
Saint Cloud, MN
Click here to add this to my saved trials
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  12/31/1969
Washington University Center for Advanced Medicine
1036
mi
from 02139
Saint Louis, MO
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 12/31/1969
Washington University Center for Advanced Medicine
1036
mi
from 02139
Saint Louis, MO
Click here to add this to my saved trials
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1036
mi
from 02139
Saint Louis, MO
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1036
mi
from 02139
Saint Louis, MO
Click here to add this to my saved trials
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  12/31/1969
Juno Research
1611
mi
from 02139
Houston, TX
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 12/31/1969
Juno Research
1611
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated:  12/31/1969
Gulf Coast Medical Research, LLC
1620
mi
from 02139
Sugar Land, TX
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status: Enrolling
Updated: 12/31/1969
Gulf Coast Medical Research, LLC
1620
mi
from 02139
Sugar Land, TX
Click here to add this to my saved trials
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
1079
mi
from 02139
Rochester, MN
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
1079
mi
from 02139
Rochester, MN
Click here to add this to my saved trials
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
268
mi
from 02139
Philadelphia, PA
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
413
mi
from 02139
Chicoutimi,
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
413
mi
from 02139
Chicoutimi,
Click here to add this to my saved trials
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1033
mi
from 02139
Saint Louis, MO
Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1033
mi
from 02139
Saint Louis, MO
Click here to add this to my saved trials
Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
Phase 1, Open-label, Single-dose Study of Evolocumab (AMG 145) Administered Subcutaneously to Subjects With Normal Renal Function or Severe Renal Impairment or End Stage Renal Disease Receiving Hemodialysis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1763
mi
from 02139
Denver, CO
Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
Phase 1, Open-label, Single-dose Study of Evolocumab (AMG 145) Administered Subcutaneously to Subjects With Normal Renal Function or Severe Renal Impairment or End Stage Renal Disease Receiving Hemodialysis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1763
mi
from 02139
Denver, CO
Click here to add this to my saved trials
The SCCS Polypill Pilot Trial
The SCCS Polypill Pilot Trial
Status: Enrolling
Updated:  12/31/1969
Franklin Primary Health Center
1236
mi
from 02139
Mobile, AL
The SCCS Polypill Pilot Trial
The SCCS Polypill Pilot Trial
Status: Enrolling
Updated: 12/31/1969
Franklin Primary Health Center
1236
mi
from 02139
Mobile, AL
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Heart Institute
2594
mi
from 02139
Los Angeles, CA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Heart Institute
2594
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
2599
mi
from 02139
Los Angeles, CA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
2599
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Stanford University
2687
mi
from 02139
Stanford, CA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Stanford University
2687
mi
from 02139
Stanford, CA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Yale-New Haven Hospital
118
mi
from 02139
New Haven, CT
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Yale-New Haven Hospital
118
mi
from 02139
New Haven, CT
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Athens Regional Medical Center
882
mi
from 02139
Athens, GA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Athens Regional Medical Center
882
mi
from 02139
Athens, GA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital
845
mi
from 02139
Chicago, IL
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital
845
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
1047
mi
from 02139
Iowa City, IA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
1047
mi
from 02139
Iowa City, IA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
2
mi
from 02139
Boston, MA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1036
mi
from 02139
Saint Louis, MO
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1036
mi
from 02139
Saint Louis, MO
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Morristown Medical Center
205
mi
from 02139
Morristown, NJ
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Morristown Medical Center
205
mi
from 02139
Morristown, NJ
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center & New York Presbyterian
182
mi
from 02139
New York, NY
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center & New York Presbyterian
182
mi
from 02139
New York, NY
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Duke Health Center at Southpoint
612
mi
from 02139
Durham, NC
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Duke Health Center at Southpoint
612
mi
from 02139
Durham, NC
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
St. Luke's University Health Network
252
mi
from 02139
Bethlehem, PA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
St. Luke's University Health Network
252
mi
from 02139
Bethlehem, PA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
477
mi
from 02139
Pittsburgh, PA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
St. Thomas Research Institute, LLC
945
mi
from 02139
Nashville, TN
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
St. Thomas Research Institute, LLC
945
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
940
mi
from 02139
Nashville, TN
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
940
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Hospital
1605
mi
from 02139
Houston, TX
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Hospital
1605
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Texas Heart Institute
1601
mi
from 02139
Houston, TX
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Texas Heart Institute
1601
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
1605
mi
from 02139
Houston, TX
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
1605
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
2483
mi
from 02139
Seattle, WA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
853
mi
from 02139
Milwaukee, WI
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
853
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hospital/Harvard Medical School
1
mi
from 02139
Boston, MA
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hospital/Harvard Medical School
1
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
NYU School of Medicine Pediatrics
186
mi
from 02139
New York, NY
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
NYU School of Medicine Pediatrics
186
mi
from 02139
New York, NY
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic Research Institute
966
mi
from 02139
Marshfield, WI
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic Research Institute
966
mi
from 02139
Marshfield, WI
Click here to add this to my saved trials
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated:  12/31/1969
Alfred Hospital
10518
mi
from 02139
Melbourne,
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status: Enrolling
Updated: 12/31/1969
Alfred Hospital
10518
mi
from 02139
Melbourne,
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
2572
mi
from 02139
Encinitas, CA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
2572
mi
from 02139
Encinitas, CA
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
2596
mi
from 02139
San Francisco, CA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
2596
mi
from 02139
San Francisco, CA
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
1216
mi
from 02139
Boca Raton, FL
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
1216
mi
from 02139
Boca Raton, FL
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
1256
mi
from 02139
Miami, FL
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
1256
mi
from 02139
Miami, FL
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
952
mi
from 02139
Sterling, IL
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
952
mi
from 02139
Sterling, IL
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
1247
mi
from 02139
Kansas City, KA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
1247
mi
from 02139
Kansas City, KA
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
1490
mi
from 02139
Salisbury, MD
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
1490
mi
from 02139
Salisbury, MD
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
353
mi
from 02139
Towson, MD
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
353
mi
from 02139
Towson, MD
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
2
mi
from 02139
Boston, MA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials